|
|
楼主 |
发表于 2025-2-21 00:22:58
|
显示全部楼层
马骏院士团队被接收一篇JAMA、一篇Cancer Cell，另有8项临床试验在进行中
0 z6 V4 V# H5 N% B \% Q1 kWhole-course Concurrent and Adjuvant Nivolumab Combined with Induction Chemotherapy Followed by Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma (NCT03984357, Cancer Cell, 2025,已接收). [6 p7 k0 O* v
' P! Q. r) z- W5 z7 v6 H8 J
Adjuvant PD-1 Antibody in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (NCT03427827, JAMA, 2025,已接收)6 C% W5 Z2 W" l8 P
8 }6 t- X- I5 B3 y6 l
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (NCT06455410, 进行中)& s7 J Q+ E. a& q7 g
Individualized Elective Neck Irradiation in NPC Patients (NCT06241612, 进行中), \, x0 f( n. I3 I
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (NCT06239727, 进行中)
% k; W! x5 @& i3 S% h# GCadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05587374, 进行中); k+ A- O7 H4 d% Z1 l/ z' {
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT05563480, completed); }1 X8 O8 p+ z- C( M8 Z7 h
Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients (NPC-LN) (NCT05389306, 进行中)
( H% @% s* e% u m! uMetronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma (NCT05342792, 进行中)
: r* S- P( a% _- eSingle-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) (NCT05044117, 进行中) |
|
发表于 2025-2-21 07:34:13
